Allscripts (MDRX) volatility flat into investor day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Cantor Fitzgerald Remains Sidelined on Allscripts (MDRX) Following Analyst Meeting
March 22, 2017 7:34 AM EDTCantor Fitzgerald reiterated a Neutral rating and $13.00 price target on Allscripts (NASDAQ: MDRX) following an analyst meeting. The company indicated that its customer satisfaction scores among US acute care hospitals improved by 16% in 2016 vs. 2015 levels. MDRX is also leveraging its investments in dbMotion... More
Jefferies Reiterates Buy on Allscripts (MDRX) Following Investor Day
March 22, 2017 7:01 AM EDTJefferies reiterated a Buy rating and $16.50 price target on Allscripts (NASDAQ: MDRX) following the company's investor day.
Analyst Sean Dodge commented, "MDRX is firmly on a path toward more sustainable revenue growth which when coupled with its lean cost structure should... More



